



THE AFRICAN MALARIA NETWORK TRUST

Fifth AMANET Biennial Conference

26-28 February 2007

Theme: Results from Clinical Development and Trials of Malaria Interventions



Zanzibar Beach Resort, Zanzibar, Tanzania
www.amanet-trust.org/fbc

Conference Programme

Sunday, 25 February 2007

14:00-21:00	Registration (Zanzibar Beach Resort)
-------------	--------------------------------------

Day 1: Monday, 26 February 2007

08.00-09.00	Registration
09:00-10:00	Opening ceremony Introductory Remarks – Prof. Wen L. Kilama , Managing Trustee, AMANET Welcome Address – Prof Francis K. Nkrumah , Chairman, AMANET Board of Trustees Opening Speech by Guest of Honour – Hon Sultan Mohammed Mugheiry , Minister for Health and Social Welfare, Zanzibar Vote of thanks - Participant
10:00-10:15	Photograph Session
10:15-10:45	Break

Session 1: Candidate Antimalarial Drugs in Preclinical Development

10:45-12:45

Chair: Prof. Francis K. Nkrumah

Rapportour: Dr Philip Agomo

10:45-11:15	Keynote address: *TBA
11:15-11:35	Design, synthesis and biological evaluation of novelpolyamine and imidazole conjugates on <i>Plasmodium falciparum</i> . Hilderbert Maurice
11:35-11:55	Activity of ZS-2A: A fraction isolated from chloroform extract of Zizyphus spina-christi against <i>Plasmodium berghei</i> in mice. Bulus Adzu
11:55-12:15	A plant-derived morphinan as a novel lead compound active against malaria liver stages. Dominique Mazier
12:15-12:35	Evaluation of the antiplasmodial effect of retinol on <i>Plasmodium berghei berghei</i> infection in mice. Ibrahim Oreagba
12:35-12:55	Differential serum expression of the C-C- chemokines MCP-1, MIP-3a, and Rantes in uncomplicated versus severe malaria in Ugandan infants. Bernard Kanoi
12:45-14:00	Lunch

Session 2: Clinical Trials of Antimalarial Drugs

14:00-17:10

Chair: Prof. Robert Guiguemde

Rapportour: Dr Christine Manyando

14:00-14:30	Keynote address: What is malaria? Endpoints for intervention trials. Prof Kevin Marsh
14:30-14:50	Efficacy and safety of Artesunate +Mefloquine (Artequin®) in the treatment of uncomplicated falciparum malaria in Ijede Community, Ikorodu LGA, Lagos State. Philip Agomo
14:50-15:10	A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in eastern Sudan. Ishag Adam
15:10-15:30	CD4 T-Cell count and HIV-1 infection in adults with uncomplicated malaria. Jean-Pierre Van geertruyden
15:30-15:50	Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in Uganda. Adoke Yeka
15:50-16:10	Molecular polymorphisms in a longitudinal Sulphadoxine-pyrimethamine regimen for the treatment of uncomplicated malaria in children in Kintampo: a baseline genetic diversity and post-treatment surveillance. Akua Agyeman-budu
16:10-16:30	Break
16:30-16:50	Efficacy and safety of artesunate + amodiaquine combination in the treatment of uncomplicated <i>falciparum</i> malaria in urban and semi rural areas of Brazzaville, Republic of Congo. Mathieu Ndounga
16:50-17:10	The question of rational treatment of malaria with artemisinin based therapy in an area with high level of drug resistance. Ademowo George
19:30	Reception

Day 2: Tuesday, 27 February 2007**Session 3: Capacity Strengthening and Trial Site Development for Malaria Interventions**

08:30-10:20

Chair: Dr Fred Kironde

Rapportour: Dr Martha Lemnge

- 08:30-09:00 Keynote address: **Dr Mahamadou Thera**
- 09:00-09:20 Challenges of Setting up a Malaria Vaccine Trial Site Development in Zambia. **Violet Siachinji**
- 09:20-09:40 Developing a clinical trial site at a district hospital to perform trials for regulatory approval. **Mbaraka Amuri**
- 09:40-10:00 Partnership in Clinical Trial Site Development. **Sharina Reyes**
- 10:00-10:20 Establishing new clinical research sites in Africa – capacity building and empowerment with a novel approach. **James Sherwood**
- 10:20-10:40 **Break**

Session 4: African Experiences on Site Characterization for Malaria Intervention Trials

10:40-13:00

Chair: Dr Tom Richie

Rapportour: Dr Abraham Hogson

- 10:40-11:10 Keynote address: **Dr Sodiomon Sirima**
- 11:10-11:30 Frequencies of glucose-6-phosphate dehydrogenase (G6PD) deficiency in children enrolled in a malaria vaccine clinical trial, at Kkombewa in Western Kenya. **Carol Hunja**
- 11:30-11:50 Molecular epidemiology of SD-PYR resistance in Uganda. **Constance Agwang**
- 11:50-12:10 The rate of selection of resistant *Plasmodium falciparum* parasite population in southeastern Tanzania, prior and after antimalarial policy change. **Allen Malisa**
- 12:10-12:30 Transmission heterogeneity bears upon malaria vaccine researches. **Vincent Robert**
- 12:30-12:50 Establishment and strengthening of sites for malaria vaccine trials in Korogwe district, Tanga region, north-eastern Tanzania Part II: Long rains malariometric survey. **Method Segeja**
- 12:50-13:00 **Summary and general discussion**
- 13:00-14:00 **Lunch**

Session 5: Candidate Malaria Vaccines in Pre-clinical Development

14:00-15:50

Chair: Dr Carter Diggs

Rapportour: Dr Thor Theander

- 14:00-14:30 Keynote address: **Dr Soren Jepsen**
- 14:30-14:50 A multi-stage, multi-antigen adenovirus-vectored vaccine against *P.falciparum* malaria. **Tom Richie**
- 14:50-15:10 Plans for clinical trials of a metabolically active, non-replicating (attenuated) *Plasmodium falciparum* sporozoite vaccine. **Judith Epstein**
- 15:10-15:30 Comparative pre-clinical assessment of the immunogenicity of *Plasmodium falciparum* merozoite stage malaria vaccine candidates. **David Arnot**
- 15:30-15:50 Rapid Identification of malaria candidate vaccines based on alpha-helical coiled coil protein motif. **Giampietro Corradin**
- 15:50-16:10 **Break**

Session 6: Clinical Trials of Candidate Malaria Vaccines

16:10-18:30

Chair: Dr Ibrahim M. Elhassan

Rapportour: Dr Seth Owusu-Agyei

- 16:10-16:40 Key note address: **Dr Robert Sauerwein**
- 16:40-17:00 Immunogenicity of FMP1 malaria vaccine in children living in a malaria endemic region of western Kenya. **Willis Okoth**
- 17:00-17:20 Safety and immunogenicity of the Plasmodium falciparum Merozoite Surface Protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. **Sodiomon Sirima**
- 17:20-17:40 Evidence of blood stage protection in a phase IIa vaccine clinical trial. Fiona Thompson
- 17:40-18:00 Glutamate-Rich Protein induces Plasmodium falciparum parasite growth inhibitory antibodies in a phase 1 malaria vaccine trial. **Michael Thiesen**
- 18:00-18:20 Low level malaria infections detected by a sensitive polymerase chain reaction and use of this technique in the evaluation of malaria vaccines in an endemic area. **Egeruan Babatunde**
- 18:20-18:30 **Summary and general discussion**

Day 3: Wednesday 28 February 2007**Session 7: Developments in malaria prevention and control Part I**

08:30-10:40

Chair: Dr Hassan Mshinda

Rapportour: Simon Kariuki

- 08:30-09:00 Keynote address: **Dr David Schellenberg**
- 09:00-09:20 Experience of the Zanzibar malaria control programme. **Abdullah Ali**
- 09:20-09:40 Dose dependant efficacy of SP-IPT for malaria in pregnancy among HIV infected Zambian women. **Victor Chalwe**
- 09:40-10:00 Impact of a pretreatment with Sulfadoxine-pyrimethamine or Artémether-lumefantrine during the high transmission season on *Plasmodium falciparum* malaria infection and clinical episodes in under five children in Burkina Faso. **Alphonse Ouedraogo**
- 10:00-10:20 Effects of Fansidar Intermittent Presumptive Treatment on pregnancy malaria, maternal anaemia and neonatal immunity in Mulago National Referral Hospital. **Fatuma Namusoke**
- 10:20-10:40 Integrated Malaria Control Programme at Obuasi, Ghana. **Steven Knowles**
- 10:40-11:00 **Break**

Session 8: Developments in malaria prevention and control Part II

11:00-13:00

Chair: Dr Thomas Sukwa

Rapportour: Dr Martin Akogbeto

- 11:00-11:30 Keynote address: **Dr Christian Lengeler**
- 11:30-11:50 Evaluation of the Efficacy of Alphacypermethrin Long Lasting Nets Developed By BASF against Wild Mosquitoes in Experimental Huts in Tanzania. **Patrick Tungu**
- 11:50-12:10 The need for local checking of the quality of insecticide treated nets (ITNs) for a sustainable management of malaria in African countries. **Martin Akogbeto**
- 12:10-12:30 Relationships between the entomological force of malaria parasite transmission by mosquitoes and the public health burden of malaria in African communities. **Charles Mbogo**
- 12:30-12:50 Entomological surveys in support of malaria vector control in Africa. **Richard H Hunt**
- 12:50-13:00 **General discussion**
- 13:00-14:00 **Lunch**

Session 9: Who is Who in Malaria Intervention Trials

14:00-17:30

Chair: Prof. Marcel Tanner

Rapportour: Prof. Joas Rugemalila

14:00-14:20	Keynote address: Prof. Wen Kilama
14:20-14:35	Global Health Programme, The Bill & Mellinda Gates Foundation. Jessica Milman , Gates Foundation
14:35-15:50	Malaria Vaccine Technology Roadmap: Progress and Action. Zarifah Reed , WHO-IVR
15:50-16:05	European Malaria Vaccine Initiative (EMVI). Odile Leroy , EMVI
16:05-16:20	The PATH Malaria Vaccine Initiative: Program Overview and Future Direction. Emily G Locke , MVI
16:20-16:35	Medicine for Malaria Venture (MMV)
16:35-16:50	Break
16:50-17:05	The approach of EDCTP in clinical trials research capacity development. Charles Mgone , European & Developing Countries Clinical Trials Partnership (EDCTP)
17:05-17:20	EU Support to Malaria Research: from FP6 to FP7. The 7th EU Research Framework Programme and the EU's Development and Cooperation Programmes. Andreas Holtel , European Community
17:20-17:30	Summary and general discussions
17:30-18:00	Closure of the Conference Feedback from the Chief Rapportours: Prof James A. Olooo and Dr Eric Achidi Prize presentations Closing remarks – Prof. Francis Nkrumah

Poster sessions: Break and Lunch times, 26-27 February 2007

1. Estimation of parasite density in malaria patients using real-time quantitative PCR amplification of parasite DNA in urine and saliva. **Davis Nwakanma**
2. Progress toward Standardizing Anti-Malaria Antibody Assays: MSP142 as an Example. **Nancy Richie**
3. RBC polymorphisms in the malaria holoendemic Lake Victoria region: implications for intervention trials. **Carolyn Kifude**
4. Results of applying an antenatal care quality improvement approach to IPT in Tanzania from 2004 through 2006. **Gaudiosa Tibaijuka**
5. Indoor collections of the Anopheles funestus group (Diptera: Culicidae) in sprayed houses in northern KwaZulu/Natal, South Africa. **Joel Moautcho**
6. Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of *Plasmodium falciparum* malaria in Sudanese patients. **Nnaemeka Iriemenam**
7. Aqueous extract of *Azadirachta indica* (neem) has the potential to be used as a larvicide in integrated malaria vector control programs. **Annabel Howard**

8. Ethnobotanique survey, chemical screening, in vivo and in vitro studies of antimalarial activity of plants used against *Plasmodium falciparum* malaria of Congolese traditional pharmacopoeia. **Nsonde Ntandou**
9. Developemnt of a molecular method for detection of mutations in *Plasmodium falciparum* adenosine triphosphatase 6, putative target of artermisins. Erasmus Kamugisha
10. Sulfadoxine-Pyrimethamine for *Plasmodium falciparum* malaria: a randomised controlled trial. **Sunny Oyakhirome**
11. Plasmodium falciparum chloroquine resistance transporter (pfcr) gene prevalence before and after artesunate plus amodiaquine combination treatment in Burkina Faso. **Issiaka Soulama**
12. Clindamycin plus Quinine: the forgotten antimalarial drug combination. **Charles Obonyo**
13. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria treated with lumefantrine-artemether (Coartem®) or Sulfadoxine-Pyrimethamine (Fansidar®). **Jean-Pierre Van geertruyden**
14. Barekuma Collaborative Community Development Project (BCCDP): developing field Site for clinical trials. **Daniel Ansong**
15. Antibodies to malaria vaccine candidates associated to chloroquine or sulfadoxine/pyrimethamine treatment efficacy in children living in endemic area of Burkina Faso. **Amidou Diarra**
16. Interferon gamma response to a T-cell epitope in *P falciparum* glutamate rich protein (GLURP) correlates with protection from clinical malaria in Ghanaian children. **Helena Nartey**
17. Low number of clinical malarial is associated with high levels of antibodies to the Apical membrane antigen - 1 (AMA-1) in Gabonese children. **David Matondo Maya**
18. A quantitative real-time Pcr method for estimation of MSP-119 Haplotype prevalence in a malaria vaccine trial. **Amos Kung'u**
19. Larvicidal properties of eight plant extracts on Anopheles gambiae mosquitoes. **Woquan Sama**
20. Description of indoor residual spraying malaria control programme as an intervention. **Paul Banda**

Oral Presentation Instructions:

1. You will have a 15 minute (30 minute for key-note address) time slot for your presentation. There will be 5 minutes for questions directly after your presentation. You will not be able to extend your time if you have technical problems during your talk. A technical assistant will be on hand for equipment operation.
2. All visuals must be in PowerPoint format. No other audio-visual medium (e.g., slide, video, or overhead) or software are allowed.
3. Prepare your presentation as a single PowerPoint file to run on an IBM compatible computer with Microsoft Office 2003. This program will run PowerPoint 2003 and all previous versions of PowerPoint. Save your file as a normal PowerPoint file (.ppt). Do not save your file as a PowerPoint Show (.pps) file.
4. All presentations must run on the Windows operating system. Conference computers will run on Windows XP. If at all possible, please create your presentation on the same version of Windows or at least test it on Windows XP before submitting it. Otherwise errors may occur in your presentation at the conference.
5. PowerPoint presentations must be submitted in advance of the conference by 09:00 am, February 26th. Email your PowerPoint presentation to Charles Wanga at clwanga@amanet-trust.org. PowerPoint presentations must be smaller than 3 MB. Name your PowerPoint file with the last name of the first author and the day and time of the presentation (e.g., Wanga_sun_1400). (Note day and time in the Conference Programme and on the website).
6. If you are unable to submit your presentation by the due date as a result of technical difficulties, special arrangements will need to be made with Charles Wanga: clwanga@amanet-trust.org
7. Bring one copy of your presentation to the conference on a CD-ROM or USB media storage device. This copy is to be used as a backup by you and the session technician if needed. Make sure the CD-ROM or presentation file is properly labelled with your name, presentation day, and time.
8. Conference organizers will load all presentations on conference computers. Presenters will NOT be allowed to use their own laptop computers. MacIntosh computers will NOT be available.
9. All presenters will be given the opportunity to check their presentations on-site, before their presentation time. There will be a preview room available and presentations may be viewed in the appropriate session room during breaks.

Poster Instructions

- Posters should be printed in landscape format on a single page measuring no more than **36"** (3ft or 91.44cm) x **56"** (4.67ft or 142.24cm). The content of each poster should be clearly divided into sections: introduction, objectives, methods, results, discussion, and conclusions.
- Poster papers should remain on display for the entire conference and may be set up beginning at 7:30 AM on February 26. At least one of the authors is expected to remain with their poster during the poster sessions